MCID: BCK003
MIFTS: 40

Background Diabetic Retinopathy

Categories: Cardiovascular diseases, Eye diseases

Aliases & Classifications for Background Diabetic Retinopathy

MalaCards integrated aliases for Background Diabetic Retinopathy:

Name: Background Diabetic Retinopathy 12 15
Non Proliferative Diabetic Retinopathy 12
Non-Proliferative Diabetic Retinopathy 12
Nonproliferative Diabetic Retinopathy 73

Classifications:



External Ids:

Disease Ontology 12 DOID:13208
ICD9CM 35 362.01 362.03
NCIt 50 C35668
SNOMED-CT 68 31411005
UMLS 73 C0004606

Summaries for Background Diabetic Retinopathy

MalaCards based summary : Background Diabetic Retinopathy, also known as non proliferative diabetic retinopathy, is related to microvascular complications of diabetes 1 and severe nonproliferative diabetic retinopathy. An important gene associated with Background Diabetic Retinopathy is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Malaria. The drugs Ranibizumab and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and testes, and related phenotype is digestive/alimentary.

Related Diseases for Background Diabetic Retinopathy

Diseases related to Background Diabetic Retinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.7 ANGPT2 INS VEGFA
2 severe nonproliferative diabetic retinopathy 32.2 ALB INS VEGFA
3 microvascular complications of diabetes 5 30.3 ALB ANGPT2 INS VEGFA
4 microvascular complications of diabetes 2 10.8
5 juvenile nasopharyngeal angiofibroma 10.2 TLR9 VEGFA
6 noma 10.1 ALB INS
7 acroosteolysis 10.1 ALB VEGFA
8 hypertensive nephropathy 10.1 ALB VEGFA
9 drug allergy 10.1 ALB INS
10 gastric lymphoma 10.1 ALB VEGFA
11 hypersensitivity reaction type iii disease 10.1 ALB TLR9
12 microvascular complications of diabetes 3 10.1 ALB INS
13 legionnaires' disease 10.1 ALB TLR9
14 fetal erythroblastosis 10.1 ALB INS
15 fascioliasis 10.1 ALB INS
16 cataract 10.1
17 diabetes mellitus 10.1
18 macular retinal edema 10.1
19 autoimmune disease of urogenital tract 10.1 ALB TLR9
20 hydrops, lactic acidosis, and sideroblastic anemia 10.1 ALB VEGFA
21 pyogenic granuloma 10.1 ANGPT2 VEGFA
22 cervix disease 10.1 TLR9 VEGFA
23 angiodysplasia 10.1 ANGPT2 VEGFA
24 lipodermatosclerosis 10.1 ANGPT2 VEGFA
25 prediabetes syndrome 10.1 ALB INS
26 keratoconjunctivitis sicca 10.1 ALB TLR9
27 macular holes 10.1 ANGPT2 VEGFA
28 vein disease 10.1 ALB VEGFA
29 hepatopulmonary syndrome 10.1 ALB VEGFA
30 meningoencephalitis 10.1 ALB TLR9
31 common cold 10.0 ALB TLR9
32 epileptic encephalopathy, childhood-onset 10.0 ANGPT2 VEGFA
33 intestinal disease 10.0 ALB TLR9 VEGFA
34 vascular disease 10.0 ALB INS VEGFA
35 keratitis, hereditary 10.0 TLR9 VEGFA
36 respiratory system disease 10.0 ALB TLR9 VEGFA
37 gastrointestinal system cancer 10.0 ALB TLR9 VEGFA
38 endocrine gland cancer 10.0 ALB TLR9 VEGFA
39 peripheral nervous system disease 10.0 ALB INS TLR9
40 type 1 diabetes mellitus 7 10.0 HBA2 INS
41 type 1 diabetes mellitus 11 10.0 HBA2 INS
42 myeloma, multiple 10.0 ALB TLR9 VEGFA
43 diabetic autonomic neuropathy 10.0 HBA2 INS
44 limb ischemia 10.0 ANGPT2 VEGFA
45 type 1 diabetes mellitus 5 10.0 HBA2 INS
46 diabetes mellitus, noninsulin-dependent 10.0
47 placental insufficiency 9.9 ANGPT2 VEGFA
48 arteries, anomalies of 9.9 ALB INS TLR9 VEGFA
49 urinary system disease 9.9 ALB INS TLR9 VEGFA
50 gastrointestinal system disease 9.9 ALB INS TLR9 VEGFA

Graphical network of the top 20 diseases related to Background Diabetic Retinopathy:



Diseases related to Background Diabetic Retinopathy

Symptoms & Phenotypes for Background Diabetic Retinopathy

MGI Mouse Phenotypes related to Background Diabetic Retinopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.02 ALB ANGPT2 INS TLR9 VEGFA

Drugs & Therapeutics for Background Diabetic Retinopathy

Drugs for Background Diabetic Retinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2 347396-82-1 459903
2
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
3
leucovorin Approved Phase 4 58-05-9 6006 143
4
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
5
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
6
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
8
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
9
Cobalamin Experimental Phase 4 13408-78-1 6438156
10 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2
11 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
13 Vitamin B 6 Phase 4
14 Vitamin B Complex Phase 4,Phase 1,Phase 2
15 Vitamin B9 Phase 4,Phase 1,Phase 2
16 Micronutrients Phase 4,Phase 2,Phase 1
17 Folate Phase 4,Phase 1,Phase 2
18 Trace Elements Phase 4,Phase 2,Phase 1
19 Hematinics Phase 4
20 Vitamins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Vitamin B 12 Phase 4
22 Vitamin B12 Phase 4
23 Insulin, Globin Zinc Phase 4,Phase 3,Not Applicable
24 insulin Phase 4,Phase 3,Not Applicable
25 Hypoglycemic Agents Phase 4,Phase 3,Not Applicable
26
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
27
Nepafenac Approved, Investigational Phase 3 78281-72-8 151075
28
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
29
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
30
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
31
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
32
Simvastatin Approved Phase 3 79902-63-9 54454
33
Fenofibrate Approved Phase 3 49562-28-9 3339
34
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
35
Zinc Approved, Investigational Phase 3,Phase 2 7440-66-6
36
Copper Approved, Investigational Phase 3,Phase 2 7440-50-8 27099
37
Tocopherol Approved, Investigational Phase 3,Phase 2,Not Applicable 1406-66-2 14986
38
Zinc oxide Approved Phase 3 1314-13-2
39
Magnesium oxide Approved Phase 3 1309-48-4 14792
40
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
41
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-02-9 14985
42
Vitamin C Approved, Nutraceutical Phase 3,Phase 2,Not Applicable 50-81-7 5785 54670067
43
Lutein Approved, Investigational, Nutraceutical Phase 3,Phase 2,Not Applicable 127-40-2 6433159
44
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
45
Ruboxistaurin Investigational Phase 3 202260-21-7, 169939-94-0 153999
46 Tocotrienol Investigational Phase 3,Phase 2,Not Applicable 6829-55-6
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
48 Anti-Inflammatory Agents, Non-Steroidal Phase 3
49 Analgesics Phase 3
50 Anti-Inflammatory Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
2 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
3 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
4 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
5 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
6 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4 Bevacizumab
7 Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
8 CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea Recruiting NCT02874313 Phase 4 Pharmacological treatment
9 A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects Unknown status NCT00908778 Phase 3 Vitreosolve;Vitreosolve
10 Nepafenac Once Daily for Macular Edema - Study 2 Completed NCT01872611 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
11 Nepafenac Once Daily for Macular Edema - Study 1 Completed NCT01853072 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
12 Intravitreal Bevacizumab for Diabetic Retinopathy Completed NCT00600262 Phase 2, Phase 3 intravitreal bevacizumab
13 Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study) Completed NCT00542178 Phase 3 Hypoglycemic Agents;Standard glycemia control;Intensive BP treatment;Standard BP control;Fenofibrate;Simvastatin;Placebo
14 Reduction in the Occurrence of Center-Involved Diabetic Macular Edema Completed NCT00090519 Phase 3 ruboxistaurin;placebo
15 Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema Completed NCT00444600 Phase 3 Triamcinolone Acetonide + laser;Ranibizumab + laser;Sham injection + laser;Ranibizumab + deferred laser
16 Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement Completed NCT01783886 Phase 3
17 Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy Recruiting NCT03702374 Phase 3 Combined antioxidant therapy
18 PROMINENT-Eye Ancillary Study (Protocol AD) Recruiting NCT03345901 Phase 3 Pemafibrate;Placebo
19 Treatment for CI-DME in Eyes With Very Good VA Study Recruiting NCT01909791 Phase 3 Prompt aflibercept;Deferred aflibercept
20 Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT02718326 Phase 3 Intravitreal aflibercept injection [IAI];Sham
21 Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy Active, not recruiting NCT02388984 Phase 3 Compound danshen dripping pills;Placebo
22 Anti-VEGF Treatment for Prevention of PDR/DME Active, not recruiting NCT02634333 Phase 3 Prompt aflibercept;Deferred aflibercept
23 Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy Terminated NCT00248131 Phase 3 Octreotide acetate in microspheres
24 Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy Terminated NCT00248157 Phase 3 Octreotide acetate in microspheres
25 A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects Terminated NCT00664183 Phase 2, Phase 3 Vitreosolve
26 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
27 Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab Unknown status NCT01845844 Phase 1, Phase 2 Ranibizumab 0.3mg/0.05cc
28 Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy Completed NCT02062034 Phase 2 Ubiquinone;Combined antioxidant therapy;Placebo
29 A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy Completed NCT02435862 Phase 2 1.0mg Luminate®;2.0mg Luminate®;3.0mg Luminate®
30 Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy Completed NCT00917553 Phase 2 doxycycline monohydrate;Placebo
31 Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment Completed NCT00198471 Phase 2 Vitrase
32 Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Completed NCT01571232 Phase 2 dexamethasone intravitreal implant;intravitreal bevacizumab
33 Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) Completed NCT01552408 Phase 1, Phase 2 0.3 mg ranibizumab
34 A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated. Recruiting NCT03238963 Phase 2 BI 1467335;Placebo
35 The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT03197870 Phase 2 AKB-9778;Placebo
36 A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR Active, not recruiting NCT02681809 Phase 2 ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection
37 A Study of Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic Retinopathy Not yet recruiting NCT03258242 Phase 2 Keluo Xin capsule;Placebo oral capsule
38 The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy Suspended NCT01880372 Phase 1, Phase 2
39 Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy Unknown status NCT02309502 Not Applicable
40 Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus Unknown status NCT01107132
41 Early Laser Treatment for Diabetic Eye Disease in China : A Pilot Randomized Trial Unknown status NCT02956759 Not Applicable
42 Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography Unknown status NCT01790945
43 Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics Unknown status NCT00698698
44 Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER) Completed NCT01440660
45 Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Completed NCT00763802
46 Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures Completed NCT01145599
47 Biomarkers of Diabetic Retinopathy Progression Completed NCT01607190
48 Computer Detection of Diabetic Retinopathy Compared to Clinical Examination Completed NCT01625598
49 Diabetes Visual Function Supplement Study Completed NCT01646047 Not Applicable
50 Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap Completed NCT02521116 Not Applicable

Search NIH Clinical Center for Background Diabetic Retinopathy

Genetic Tests for Background Diabetic Retinopathy

Anatomical Context for Background Diabetic Retinopathy

MalaCards organs/tissues related to Background Diabetic Retinopathy:

41
Eye, Endothelial, Testes, Brain, Colon, Pancreas, Cervix

Publications for Background Diabetic Retinopathy

Articles related to Background Diabetic Retinopathy:

(show all 36)
# Title Authors Year
1
Role of combined phacoemulsification and intravitreal injection of bevacizumab in prevention of postoperative macular edema in non-proliferative diabetic retinopathy. ( 30197955 )
2018
2
Plasma metabolic profile reveals PGF2α protecting against non-proliferative diabetic retinopathy in patients with type 2 diabetes. ( 29408756 )
2018
3
The Correlation between Changes in Biochemical Parameters and Central Macular Thickness in Patients with Non-Proliferative Diabetic Retinopathy. ( 29644239 )
2018
4
Successful Midterm Management With an Herbal Decoction, Modified-Goshajinkigan (mGJG) for Non-Proliferative Diabetic Retinopathy: A Case Study. ( 29793732 )
2018
5
Nomogram for prediction of non-proliferative diabetic retinopathy in juvenile-onset type 1 diabetes: a cohort study in an Asian population. ( 30111889 )
2018
6
The unmet need for better risk stratification of non-proliferative diabetic retinopathy. ( 30474144 )
2018
7
Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy. ( 28367202 )
2017
8
Pupillary responses in non-proliferative diabetic retinopathy. ( 28332564 )
2017
9
Effects of photocoagulation on ocular blood flow in patients with severe non-proliferative diabetic retinopathy. ( 28355247 )
2017
10
Aqueous humor endothelin-1 and total retinal blood flow in patients with non-proliferative diabetic retinopathy. ( 28548649 )
2017
11
Aqueous humour concentrations of TGF-β, PLGF and FGF-1 and total retinal blood flow in patients with early non-proliferative diabetic retinopathy. ( 28631371 )
2017
12
Non-proliferative diabetic retinopathy symptoms detection and classification using neural network. ( 28786703 )
2017
13
Automatic non-proliferative diabetic retinopathy screening system based on color fundus image. ( 29073912 )
2017
14
COMPARISON OF 3 MM × 3 MM VERSUS 6 MM × 6 MM OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY SCAN SIZES IN THE EVALUATION OF NON-PROLIFERATIVE DIABETIC RETINOPATHY. ( 29190249 )
2017
15
Fundus autofluorescence lifetimes are increased in non-proliferative diabetic retinopathy. ( 27519815 )
2017
16
Aqueous humour concentrations of TGF-β, PLGF and FGF-1 and total retinal blood flow in patients with early non-proliferative diabetic retinopathy. ( 27678201 )
2017
17
Association of macular pigment optical density with early stage of non-proliferative diabetic retinopathy in Chinese patients with type 2 diabetes mellitus. ( 27803860 )
2016
18
Effect of focal laser photocoagulation in eyes with mild to moderate non-proliferative diabetic retinopathy. ( 27803861 )
2016
19
The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study. ( 26207797 )
2016
20
The effect of ubiquinone and combined antioxidant therapy on oxidative stress markers in non-proliferative diabetic retinopathy: A phase IIa, randomized, double-blind, and placebo-controlled study. ( 26321469 )
2016
21
The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients. ( 27378278 )
2016
22
Characterisation of human non-proliferative diabetic retinopathy using the fractal analysis. ( 26309878 )
2015
23
Non-Proliferative Diabetic Retinopathy: is It Cost-Effective to Treat Early? ( 27202121 )
2014
24
The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. ( 23551550 )
2013
25
From minimal background diabetic retinopathy to profuse sight threatening vitreoretinal haemorrhage: management issues in a case of pregestational diabetes and pregnancy. ( 12873299 )
2003
26
Massive subretinal bleed in a patient with background diabetic retinopathy and on treatment with warfarin. ( 12855977 )
2003
27
Background diabetic retinopathy in Harare, Zimbabwe. ( 10448253 )
1999
28
Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. ( 9519746 )
1998
29
Bovine factor VIII derivative in the treatment of non-proliferative diabetic retinopathy. ( 7630622 )
1995
30
Contrast sensitivity changes in background diabetic retinopathy. ( 2013027 )
1991
31
Does increased platelet aggregation have a prognostic value in the deterioration of background diabetic retinopathy? The Damad Study Group. ( 2270529 )
1990
32
Treatment of background diabetic retinopathy. ( 3508804 )
1987
33
Pattern electroretinograms become abnormal when background diabetic retinopathy deteriorates to a preproliferative stage: possible use as a screening test. ( 3964635 )
1986
34
Blood pressure and the progression of mild background diabetic retinopathy. ( 4077241 )
1985
35
Effect of pure O2-breathing on retinal blood flow in normals and in patients with background diabetic retinopathy. ( 6690224 )
1984
36
Vitreous fluorophotometry and hemoglobin AIc in non-proliferative diabetic retinopathy. ( 6933817 )
1980

Variations for Background Diabetic Retinopathy

Expression for Background Diabetic Retinopathy

Search GEO for disease gene expression data for Background Diabetic Retinopathy.

Pathways for Background Diabetic Retinopathy

GO Terms for Background Diabetic Retinopathy

Cellular components related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 ALB ANGPT2 COLEC12 HBA2 INS VEGFA
2 extracellular region GO:0005576 9.17 ALB ANGPT2 HBA2 INS ITIH2 TLR9
3 blood microparticle GO:0072562 9.13 ALB HBA2 ITIH2

Biological processes related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.33 ALB INS ITIH2
2 receptor-mediated endocytosis GO:0006898 9.13 ALB COLEC12 HBA2
3 positive regulation of protein autophosphorylation GO:0031954 8.62 INS VEGFA

Molecular functions related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxygen binding GO:0019825 8.96 ALB HBA2
2 signaling pattern recognition receptor activity GO:0008329 8.62 COLEC12 TLR9

Sources for Background Diabetic Retinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....